Overall, these findings validate a novel procedure for evaluating candidate analgesic effects on pain-related behavioral depression in mice and support continued research with low- to intermediate-efficacy MOR agonists as a strategy to retain analgesic effectiveness with improved safety. Here, OPRM1 is linked to depressive symptom measurement.